Prostate 25-hydroxyvitamin D-1α-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor

Anticancer Research

Volumn 28, Issue 4 A, 2008, Pages 2009-2013

  Wang, Lilin ^a   Persons, Elly S ^a   Jamieson, Dan ^a   Flanagan, John N ^a,d   Hsu, Hui H ^a   Holick, Michael F ^a   Luo, Z ^a   Sakaki, Toshi ^c   Urushino, N ^c   Faller, Douglas V ^b   Chen, Tai C ^a,b  

^a Section of Endocrinology Diabetes and Nutrition

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CYP27B1; Histone deacetylase inhibitor; Prostate cancer; Vitamin D hydroxylase

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; EPIDERMAL GROWTH FACTOR; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; MESSENGER RNA; VORINOSTAT; HYDROXAMIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CHROMATIN; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REPORTER GENE; TUMOR DIFFERENTIATION; TUMOR GROWTH; UPREGULATION; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; EPITHELIUM CELL; GENETICS; MALE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; CELL GROWTH PROCESSES; CELL LINE, TRANSFORMED; EPITHELIAL CELLS; HUMANS; HYDROXAMIC ACIDS; MALE; PROMOTER REGIONS (GENETICS); PROSTATE; RNA, MESSENGER; UP-REGULATION;

EID: 48549103658     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Schwartz GG and Chen TC: Vitamin D, sunlight, and the natural history of prostate cancer. Vitamin D, 2nd edition. Feldman Glorieux and Pike (eds.). Academic Press pp. 1599-1615, 2005.
2. Miller G: Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Met Rev 17: 353-360, 1999.
3. Jones G, Strugnell SA and DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev 78: 1193-1231, 1998.
4. Omdahl JL, Morris HA and May K: Hydroxylase enzyme of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 22: 139-166, 2002.
5. Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF and Chen TC: 25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer and is enhanced by gene transfer. J Steroid Biochem Mol Biol 81: 135-140, 2002.
6. Young MV, Schwartz GG, Wang L, Jamieson, DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF and Chen TC: Prostate 25-hydroxyvitamin D-1α-hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25: 967-971, 2004.
7. Wang L, Flanagan JN, Jamieson, DP, Holick MF and Chen TC: Regulation of 25-hydroxyvitamin D-1α-hydroxylase by epidermal growth factor in prostate cells. J Steroid Biochem Mol Biol 89-90C: 127-130, 2004.
8. Hodawadekar SC and Marmorstein R: Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26: 5528-5540, 2007.
9. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007.
10. Marks PA and Dokamnovic M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511, 2005.
11. WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
12. 3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. J Invest Dermatol 104: 113-117, 1995.
13. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
14. Wang L, Whitlatch LW, Flanagan JN, Holick MF and Chen TC: Vitamin D autocrine system and prostate cancer. Recent Results in Cancer Research. In: Vitamin D Analogs in Cancer Prevention and Therapy. Reichrath J, Friedrich M and Tilgen W (eds.), Springer-Verlag, Berlin 164: 223-237, 2003.
15. Flanagan JN, Young MV, Persons KS, Wang L, Whitlatch LW, Holick MF and Chen TC: Human prostate cells can synthesize 1α,25-dihydroxyvitamin D from vitamin D: Implication for prostate cancer chemoprevention by vitamin D. Anticancer Res 26: 2567-2572, 2006.
16. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-821, 2007.
17. 3. Biochemistry 25: 1545-1548, 1986.
18. Bikle DD: What is new in vitamin D: 2006-2007. Curr Opin Rheumatol 19: 383-388, 2007.
19. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
20. Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68(4): 917-932, 2005.
21. Kong XF, Zhu XH, Pei YL, Jackson DM and Holick MF: Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D-1α-hydroxylase gene. Proc Natl Acad Sci USA 96: 6988-6993, 1999.